NIH awards RXi with SBIR grants to develop novel RNAi therapeutics

[News]

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.

More... (http://www.news-medical.net/news/20110427/NIH-awards-RXi-with-SBIR-grants-to-develop-novel-RNAi-therapeutics.aspx)